MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Ocular Therapeutix Inc

Fermé

SecteurSoins de santé

11.32 -0.53

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.21

Max

11.5

Chiffres clés

By Trading Economics

Revenu

-16M

-64M

Ventes

-6.4M

11M

Marge bénéficiaire

-602.342

Employés

274

EBITDA

-20M

-64M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+56.44% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

471M

1.8B

Ouverture précédente

11.85

Clôture précédente

11.32

Sentiment de l'Actualité

By Acuity

50%

50%

169 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Ocular Therapeutix Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 juil. 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 juil. 2025, 21:14 UTC

Acquisitions, Fusions, Rachats

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 juil. 2025, 21:04 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 juil. 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 juil. 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 juil. 2025, 22:47 UTC

Acquisitions, Fusions, Rachats

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 juil. 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 juil. 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 juil. 2025, 22:43 UTC

Acquisitions, Fusions, Rachats

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 juil. 2025, 22:43 UTC

Acquisitions, Fusions, Rachats

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 juil. 2025, 22:40 UTC

Acquisitions, Fusions, Rachats

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 juil. 2025, 22:40 UTC

Acquisitions, Fusions, Rachats

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 juil. 2025, 22:30 UTC

Market Talk
Résultats

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 juil. 2025, 22:20 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

17 juil. 2025, 22:20 UTC

Market Talk
Résultats

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 juil. 2025, 22:04 UTC

Market Talk
Résultats

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 juil. 2025, 22:03 UTC

Acquisitions, Fusions, Rachats

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 juil. 2025, 21:58 UTC

Market Talk
Résultats

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 juil. 2025, 21:57 UTC

Résultats

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 juil. 2025, 21:47 UTC

Résultats

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 juil. 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 juil. 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 juil. 2025, 21:38 UTC

Acquisitions, Fusions, Rachats

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 juil. 2025, 21:22 UTC

Acquisitions, Fusions, Rachats

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 juil. 2025, 21:05 UTC

Résultats

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 juil. 2025, 21:04 UTC

Acquisitions, Fusions, Rachats

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 juil. 2025, 21:02 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 juil. 2025, 20:59 UTC

Acquisitions, Fusions, Rachats

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 juil. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

17 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Ocular Therapeutix Inc prévision

Objectif de Prix

By TipRanks

56.44% hausse

Prévisions sur 12 Mois

Moyen 17.6 USD  56.44%

Haut 22 USD

Bas 14 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

11

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

6.97 / 7.62Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

169 / 376Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.